{
  "paper_id": "PMC11802505",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802505/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "The molecular alterations associated with cancer progression from normal skin to AK to cSCC. Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11802505/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/32231d77b0f8/fimmu-16-1518633-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Molecular alterations that drive cutaneous squamous cell carcinoma (cSCC) proliferation.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11802505/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/0c0ba57ce2ff/fimmu-16-1518633-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Current clinical drugs used in the management of AK and cSCC.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "f3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11802505/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ba9/11802505/e79292f6950a/fimmu-16-1518633-g003.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Schematic depicting the spectrum of morphologies of NS-AK-cSCC lesions, with relevant changes in gene expression.Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Identifying specific genomic changes that drive the transition from normal skin (NS) to AK and subsequently to invasive cSCC is challenging, given the substantial burden of UVR-induced mutations characteristic of all stages of this progression (\nFigure 1\n).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular genetic studies have examined AK and cSCC for known cancer gene expressions, chromosomal instability, and mutation levels (\nFigure 2\n).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Below is an overview of the current clinical drugs used in the management of AK and cSCC (\nFigure 3\n).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 39,
    "images_downloaded": 3,
    "tables_filtered": 58
  }
}